8-K 1 a17-1600_18k.htm 8-K

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 3, 2017

 


 

NABRIVA THERAPEUTICS AG

(Exact Name of Registrant as Specified in its Charter)

 


 

Republic of Austria

 

001-37558

 

Not applicable

(State or Other Jurisdiction
of Incorporation

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

Leberstrasse 20
1110 Vienna, Austria

 

Not applicable

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code:  +43 (0)1 740 930

 

Not applicable

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.02  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 3, 2017, J. Peter Wolf, General Counsel and Corporate Secretary of Nabriva Therapeutics AG (the “Company”) notified the Company that he will resign from his positions, effective February 7, 2017, to pursue other opportunities. The Company has commenced a search for Mr. Wolf’s successor.

 

Item 7.01  Regulation FD Disclosure.

 

The Company intends to meet with investors and analysts over the course of the next several weeks. A copy of the materials to be presented at these meetings is attached hereto as Exhibit 99.1 and is incorporated by reference into this Item 7.01. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01  Financial Statements and Exhibits.

 

(d)           Exhibits

 

See Exhibit Index attached hereto.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

NABRIVA THERAPEUTICS AG

 

 

Date: January 9, 2017

By:

/s/ Colin Broom

 

 

Colin Broom
Chief Executive Officer

 

3



 

EXHIBIT INDEX

 

Exhibit No.

 

Description

99.1

 

Presentation materials dated January 2017

 

4